BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patterson CM, Balachander SB, Grant I, Pop-Damkov P, Kelly B, McCoull W, Parker J, Giannis M, Hill KJ, Gibbons FD, Hennessy EJ, Kemmitt P, Harmer AR, Gales S, Purbrick S, Redmond S, Skinner M, Graham L, Secrist JP, Schuller AG, Wen S, Adam A, Reimer C, Cidado J, Wild M, Gangl E, Fawell SE, Saeh J, Davies BR, Owen DJ, Ashford MB. Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol 2021;4:112. [PMID: 33495510 DOI: 10.1038/s42003-020-01631-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Bai L, Hou L, Deng H, Luan S, Liu D, Huang M, Zhao L. Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114184] [Reference Citation Analysis]
2 Basu A. The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy. Pharmacol Ther 2021;:107943. [PMID: 34182005 DOI: 10.1016/j.pharmthera.2021.107943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Arulananda S, O'Brien M, Evangelista M, Jenkins LJ, Poh AR, Walkiewicz M, Leong T, Mariadason JM, Cebon J, Balachander SB, Cidado JR, Lee EF, John T, Fairlie WD. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discov 2021;7:122. [PMID: 34050131 DOI: 10.1038/s41420-021-00505-0] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Kumar N, Fazal S, Miyako E, Matsumura K, Rajan R. Avengers against cancer: A new era of nano-biomaterial-based therapeutics. Materials Today 2021;51:317-49. [DOI: 10.1016/j.mattod.2021.09.020] [Reference Citation Analysis]
5 Ashford MB, England RM, Akhtar N. Highway to Success—Developing Advanced Polymer Therapeutics. Adv Therap 2021;4:2000285. [DOI: 10.1002/adtp.202000285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer 2021. [PMID: 34663943 DOI: 10.1038/s41568-021-00407-4] [Reference Citation Analysis]
7 Fairlie WD, Lee EF. Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer. Int J Mol Sci 2021;22:2841. [PMID: 33799592 DOI: 10.3390/ijms22062841] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Carpenter V, Saleh T, Min Lee S, Murray G, Reed J, Souers A, Faber AC, Harada H, Gewirtz DA. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. Biochem Pharmacol 2021;193:114765. [PMID: 34536356 DOI: 10.1016/j.bcp.2021.114765] [Reference Citation Analysis]
9 Vasalou C, Ferguson D, Li W, Muse V, Gibbons FD, Sonzini S, Zhang G, Pop-Damkov P, Gangl E, Balachander SB, Wen S, Schuller AG, Puri S, Mazza M, Ashford M, Fretland AJ, McGinnity DF, Jones RDO. Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes. Mol Pharm 2022;19:172-87. [PMID: 34890209 DOI: 10.1021/acs.molpharmaceut.1c00715] [Reference Citation Analysis]
10 Fairlie WD, Lee EF. Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers. Biochem Soc Trans 2021;49:2397-410. [PMID: 34581776 DOI: 10.1042/BST20210750] [Reference Citation Analysis]
11 Hafezi S, Rahmani M. Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives. Cancers (Basel) 2021;13:1292. [PMID: 33799470 DOI: 10.3390/cancers13061292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Pal P, Thummuri D, Lv D, Liu X, Zhang P, Hu W, Poddar SK, Hua N, Khan S, Yuan Y, Zhang X, Zhou D, Zheng G. Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition. J Med Chem 2021;64:14230-46. [PMID: 34533954 DOI: 10.1021/acs.jmedchem.1c00517] [Reference Citation Analysis]
13 Perez JJ, Perez RA, Perez A. Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering. Front Mol Biosci 2021;8:681617. [PMID: 34095231 DOI: 10.3389/fmolb.2021.681617] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Chadar R, Afsana, Kesharwani P. Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer. Int J Pharm 2021;605:120835. [PMID: 34197908 DOI: 10.1016/j.ijpharm.2021.120835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Prasanna PG, Citrin DE, Hildesheim J, Ahmed MM, Venkatachalam S, Riscuta G, Xi D, Zheng G, van Deursen J, Goronzy J, Kron SJ, Anscher MS, Sharpless NE, Campisi J, Brown SL, Niedernhofer LJ, O'Loghlen A, Georgakilas AG, Paris F, Gius D, Gewirtz DA, Schmitt CA, Abazeed ME, Kirkland JL, Richmond A, Romesser PB, Lowe SW, Gil J, Mendonca MS, Burma S, Zhou D, Coleman CN. Therapy-Induced Senescence: Opportunities to Improve Anti-Cancer Therapy. J Natl Cancer Inst 2021:djab064. [PMID: 33792717 DOI: 10.1093/jnci/djab064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Hamilton C, Fox JP, Longley DB, Higgins CA. Therapeutics Targeting the Core Apoptotic Machinery. Cancers (Basel) 2021;13:2618. [PMID: 34073507 DOI: 10.3390/cancers13112618] [Reference Citation Analysis]
17 Lee EF, Fairlie WD. Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer. Biochem Soc Trans 2021;49:2381-95. [PMID: 34515749 DOI: 10.1042/BST20210749] [Reference Citation Analysis]
18 Gopalsamy A. Selectivity through Targeted Protein Degradation (TPD). J Med Chem 2022. [PMID: 35658428 DOI: 10.1021/acs.jmedchem.2c00397] [Reference Citation Analysis]
19 Åslund AKO, Vandebriel RJ, Caputo F, de Jong WH, Delmaar C, Hyldbakk A, Rustique E, Schmid R, Snipstad S, Texier I, Vernstad K, Borgos SEF. A comparative biodistribution study of polymeric and lipid-based nanoparticles. Drug Deliv and Transl Res . [DOI: 10.1007/s13346-022-01157-y] [Reference Citation Analysis]